Saturday, April 20, 2024
4/20/2024
PROJECT SUMMARY/ABSTRACT Leukemia patients bearing MLL1 rearrangement generally display very poor prognosis, demanding new treatment strategies. Multiple independent studies have identified EZH2, a histone methyltransferase and catalytic subunit of Polycomb Repressive Complex 2 (PRC2), as an attractive drug target in MLL1-rearranged leukemias. However, the current catalytic inhibitors of EZH2 have limited anti-tumor effect. Our preliminary studies show that EZH2 also binds c-MYC and has a non-canonical function in activation of oncogenes (such as Cyclin E1) in MLL1-rearranged leukemias, which differs from the well-known PRC2:EZH2-driven canonical function related to gene repression. In order to target both canonical and non-canonical oncogenic actions by EZH2, we used the Proteolysis Targeting Chimera (PROTAC) technology to generate novel EZH2 small- molecule degraders including MS177. Our extensive preliminary studies have demonstrated that MS177 effectively degrades both PRC2:EZH2 and non-PRC2 partners of EZH2 (e.g., c-MYC, which binds EZH2 to activate oncogenes), thus suppressing both canonical and non-canonical oncogenic activities of EZH2 in tumor. Importantly, our preliminary results also show that MS177 is superior to all of enzymatic inhibitors of EZH2 in treating MLL1-rearranged leukemias. Thus, we hypothesize that: (1) EZH2 has a less-studied, non- canonical oncogenic function, which acts in parallel with the PRC2:EZH2-dependent one to produce more aggressive tumor phenotypes seen in MLL1-rearranged leukemias; and (2) targeting both canonical and non- canonical activities of EZH2 by PROTACs represents a novel and superior therapeutic strategy to inhibition of EZH2’s enzymatic activity alone. Dissection of the mechanisms underlying EZH2-mediated oncogenesis and development of an optimal EZH2 PROTAC as a drug candidate will have significant impact on improving treatments for MLL1-rearranged leukemia patients. Towards this goal, we will further characterize such a new non-canonical oncogenic role of EZH2 in MLL1-rearranged leukemias (Aim 1a) and define effects of EZH2 PROTACs on suppressing both canonical and non-canonical oncogenic activities of EZH2 (Aim 1b). We will also determine in vitro and vivo therapeutic effects of EZH2 PROTACs by employing multiple independent MLL1-rearranged leukemia models including human/murine cancer cells and patient-derived xenografts (PDX) (Aim 2). Lastly, we will optimize our EZH2 PROTAC leads into a drug candidate (Aim 3). Completion of the proposed research will not only provide novel mechanistic understanding of how MLL1-rearranged leukemias develop, but will also validate an innovative therapeutic strategy and deliver a promising therapeutic candidate for the treatment of affected cancer patients.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
